Liquidia Surges After $381 Million Settlement with United Therapeutics for Lung Disease Drug

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank. Whether that price was a bargain or a slow bleed depends on one number Liquidia has not yet revealed.

Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug

Oct 14 (Reuters) - Liquidia shares jumped nearly 40% in premarket trading on Wednesday after the drugmaker settled a years-long legal dispute with United Therapeutics over its lung disease ​drug. The settlement, announced late on Tuesday, ends six laws...

Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle (LQDA:NASDAQ)

Liquidia (LQDA) shares jumped 42% after the company reached a $380.7M settlement with United Therapeutics (UTHR),

What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Liquidia Shares Climb 27% After Settlement Resolves Pending Litigation

The shares closed at $33.94 on Oct. 14, up $7.13 from the previous close.

Liquidia Stock Soars More Than 26% After $380.7 Million Settlement Ends Legal War With United Therapeutics

Liquidia shares jumped after the drugmaker agreed to pay United Therapeutics $380.7 million, ending six lawsuits and securing continued sales of Yutrepia for PAH.